



12 May 2022

Director Resignation



DIRECTOR RESIGNATION

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, advises Mr Harry Karelis has resigned from the position of Non-Executive Vice Chairman effective today, 12 May 2022.

The Board wishes to thank Mr Karelis for his significant contribution to the Company and wish him all the best with his future endeavours.

This announcement has been approved and authorised for release by the board of Zelira Therapeutics Limited.

Tim Slate

Non-Executive Director and Company Secretary



For further information
please contact

Company

Dr Oludare Odumosu
Managing Director & CEO
☎ +1 909 855 0675
✉ oodumosu@zeliratx.com

Investors

Ronn Bechler
Executive Chairman, Market Eye
☎ +61 400 009 774
✉ ronn.bechler@marketeye.com.au

About Zelira Therapeutics

Australia

Level 3, 101 St Georges Terrace
Perth WA 6000, AUSTRALIA
☎ +61 8 6558 0886
Fax: +61 8 6316 3337
✉ enquiries@zeliratx.com
www.zeliratx.com
ACN 103 782 378

USA

5110 Campus Drive, Suite 150
Plymouth Meeting, PA 19462
United States Of America
☎ +1 484-630-0650

About Zelira www.zeliratx.com



Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), is a leading global biopharmaceutical development and commercialization company marketing cannabinoid-based medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to access the world's largest and fastest growing markets. The Company is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain as well as offering over the counter (OTC) products.

The Company has two proprietary formulations under the HOPE® brand that are generating revenues in Australia, Louisiana and Washington D.C. with other States in the US expected to follow.

Zelira is also generating revenue in Australia and Germany from its proprietary and patented Zenivol® - a leading cannabinoid-based medicine for treatment of chronic insomnia. Zenivol® has successfully completed the world's first cannabinoid-based efficacy trial for chronic insomnia where it was found to be a safe and effective treatment. This clinical trial was published in the prestigious peer-reviewed journal SLEEP®.

In 2020, Zelira partnered with SprinJene® Natural to develop and commercialise natural and organic oral care products under the SprinjeneCBD brand, as part of Zelira's OTC business. The SprinjeneCBD toothpaste product is the first of several scientifically formulated, hemp-derived, oral care products containing cannabinoids and based on the proprietary and patented technology of Blackseed oil and Zinc.

The Company has worked in partnership with world-leading researchers and organisations, which since inception include Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.